ClinicalTrials.gg
RecruitingNCT06361238Updated Dec 20, 2024

Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery

A Phase 3 interventional study of Liraglutide injection and Placebo injection in Delirium, Postoperative, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Recruiting at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-12-20.

Sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 185 studies in Emergence Delirium with a site in China — 64 open to participants now, 65 under way, 1 of them phase 3. Emergence Delirium · China.

Planned enrollment
46th of 111
260 · median 225
Started
2024
with 29 others
Phase 3
5 of 185
1 open now
Primary completion
2027-03
later than 47 of 64 live
Registered
102nd of 185
by date

Among the 185 studies in Emergence Delirium with a site in China, this one is the 46th largest by planned enrollment of the 111 interventional ones that give a count, is one of 30 that started in 2024, is one of 5 in phase 3, reaches primary completion later than 47 of the 64 other live ones, and was the 102nd registered.

Emergence Delirium

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

Browse Emergence Delirium studies →

Open to participants now

64 of the 185 studies in Emergence Delirium with a site in China are open now. Recruiting first, the newest first:

58 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Emergence Delirium with a site in China, or all of them as a file.
02

Study summary

This study aims to clarify the preventive effect of perioperative liraglutide application on postoperative delirium in elderly patients with Type 2 diabetes undergoing cardiac surgery.

Read the detailed description

Delirium is the most prevalent neurological complication following cardiac surgery. It is characterized by an acute and fluctuating disturbance in consciousness, attention, and cognitive function. The incidence of delirium post-cardiac surgery ranges between 11% and 46%. It is closely linked to increased postoperative mortality, extended hospital stays, higher healthcare costs, and long-term cognitive impairment. Currently, it is widely recognized that the development of delirium is influenced by multiple factors, including advanced age, diabetes, surgical and anesthetic techniques, depression, baseline cognitive function, and infections, among others.

Inflammatory responses, crucial for protecting against external or internal threats, can, following surgery, lead to neuroinflammation and neurological damage due to elevated postoperative inflammatory markers and blood-brain barrier disruption. The involvement of microglia and astrocytes, key players in the central nervous system's immune response, has been identified in mediating postoperative delirium, making them potential targets for prevention.

Liraglutide, a Glucagon-like peptide-1 receptor agonist primarily used for treating Type 2 diabetes, has shown promise in mitigating neurocognitive damage associated with diabetes and Alzheimer's disease, suggesting its potential in preventing postoperative delirium in cardiac surgery patients with Type 2 diabetes. Preliminary animal studies and a randomized controlled trial indicate that perioperative liraglutide application could reduce the incidence of postoperative delirium by inhibiting glial activation and the subsequent neuroinflammatory response. However, differences in patient demographics, disease severity, and dosing in previous studies highlight the need for further investigation.

The study aims to investigate whether the perioperative administration of liraglutide can prevent the onset of postoperative delirium in elderly patients with Type 2 diabetes undergoing cardiac surgery. Secondary objectives include assessing the impact on the severity and duration of delirium, cognitive function, anxiety, depression, cardiac function, cardiovascular events, ICU stay, mechanical ventilation duration, and levels of serum markers for brain injury, inflammation, myocardial damage, and cardiac function.

03

Conditions studied

  • Delirium, Postoperative

Browse trials for

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 60 years
  2. Type 2 diabetes
  3. Patients undergoing elective cardiac surgery

Exclusion criteria

Exclusion Criteria:

  1. History of neurological or psychiatric disorders, such as schizophrenia, epilepsy, Parkinson's disease, severe dementia, etc
  2. Patients with communication difficulties, such as severe visual, auditory, or speech impairments
  3. History of central nervous system damage or surgery
  4. Cardiac function Class IV
  5. Severe liver dysfunction ( Class C)
  6. Severe renal failure requiring renal replacement therapy
  7. History of pancreatitis
  8. Type 1 diabetes
  9. Patients whose blood sugar is difficult to control within 4-8 mmol/L during the screening period
  10. Patients with medullary thyroid carcinoma or a family history of it
  11. Pregnant or breastfeeding women
  12. Intolerance or allergy to liraglutide
  13. Previous use of GLP-1A and SGLT2i
  14. Patients who refuse to sign the
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Liraglutide Group

    Subcutaneous injection of liraglutide

    Drug: Liraglutide injection

  • Placebo comparator
    Vehicle Group

    Subcutaneous injection of vehicle

    Drug: Placebo injection

Interventions

  • DrugLiraglutideStudies of LiraglutideLiraglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subcutaneous injection of liraglutide: 0.6 mg administered the day before surgery, 1.8 mg administered post-anesthesia induction on the day of surgery, followed by 0.6 mg daily for the first three postoperative days.

    Also known as: Victoza

  • DrugPlacebo injection

    Subcutaneous injection of Placebo: the same volume as liraglutide administrated at the corresponding times.

    Also known as: Normal saline

06

What researchers measure

Primary outcomes

  1. The incidence of delirium

    Confusion Assessment Method (CAM), or its variant for the Intensive Care Unit, known as CAM-ICU, is the tool used to assess the incidence of delirium. For CAM, the scale ranges from a minimum value of 11 to a maximum of 44, with higher scores indicating a worse outcome. In contrast, CAM-ICU does not utilize a numerical scale; it is a qualitative assessment designed to evaluate confusion without assigning specific values.

    Time frame: One day before surgery and within the first seven days after surgery.

Secondary outcomes

  1. The severity of delirium

    The CAM-Severity Scale (CAM-S), available in both short-form and long-form versions, serves as a tool for assessing the severity of delirium. The scale extends from 0 to 7 in its short-form and from 0 to 19 in its long-form. Higher scores on the CAM-S are indicative of more severe outcomes.

    Time frame: One day before surgery and within the first seven days after surgery.

  2. Cognitive function

    Minimum Mental State Examination (MMSE) is the tool used to assess cognitive function. The scale extends from 0 to 30, with higher scores indicating a better outcome.

    Time frame: One day before surgery; one week after surgery or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.

  3. Anxiety

    Generalized anxiety disorder-7 (GAD-7) is the tool used to assess anxiety. The scale extends from 0 to 21, with higher scores indicating a worse outcome.

    Time frame: One day before surgery; one week after surgery or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.

  4. Depression

    Patient Health Questionnaire-9 (PHQ-9) is the tool used to assess depression. The scale extends from 0 to 27, with higher scores indicating a worse outcome.

    Time frame: One day before surgery; one week after surgery or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.

  5. Duration of ICU stay

    By retrieving the Hospital Information System and ICU special care sheet

    Time frame: The time from transfer into the ICU to discharge from the ICU, assessed up to 12months.

  6. Mechanical ventilation time

    By retrieving the Hospital Information System and ICU special care sheet

    Time frame: The time from tracheal intubation to the removal of the tracheal tube, assessed up to 12months.

  7. Duration of hospital stay

    By retrieving the Hospital Information System

    Time frame: The time from hospital admission to discharge, assessed up to 12months.

  8. In-hospital mortality

    By retrieving the Hospital Information System

    Time frame: The time from hospital admission to discharge, assessed up to 12months.

  9. Incidence of adverse events

    By retrieving the Hospital Information System, ICU special care sheet and follow-up

    Time frame: One day preoperatively to three days Postoperatively.

  10. Rate of major cardiovascular adverse events

    By retrieving the Hospital Information System, ICU special care sheet and follow-up

    Time frame: Within 1 year post-surgery (including cardiovascular death, myocardial infarction, and stroke)

  11. Serum levels of NSE

    ELISA

    Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively

  12. Serum levels of CRP

    ELISA

    Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively

  13. Serum levels of IL-1α

    ELISA

    Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively

  14. Serum levels of TNF-α

    ELISA

    Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively

  15. Serum levels of C3

    ELISA

    Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively

  16. Serum levels of LDH

    ELISA

    Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively

  17. Serum levels of CK

    ELISA

    Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively

  18. Serum levels of CK-MB

    ELISA

    Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively

  19. Serum levels of AST

    ELISA

    Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively

  20. Serum levels of cTNT

    ELISA

    Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively

  21. Serum levels of BNP

    ELISA

    Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively

  22. Serum levels of C1q

    ELISA

    Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively

  23. Serum levels of IL-1β

    ELISA

    Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively

  24. Serum levels of IL-6

    ELISA

    Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively

  25. Serum levels of S100β

    ELISA

    Time frame: One day preoperatively; immediately after admission to ICU; 3 days and 7 days postoperatively

  26. Left Ventricular Posterior Wall Thickness in Diastole (LVPWTd)

    The echocardiography is used to assess the LVPWTd.

    Time frame: One day preoperatively; One week postoperatively or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.

  27. Left Ventricular End-Diastolic Dimension (LVDd)

    The echocardiography is used to assess the LVDd.

    Time frame: One day preoperatively; One week postoperatively or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.

  28. Left Ventricular End-Systolic Diameter (LVDs)

    The echocardiography is used to assess the LVDs.

    Time frame: One day preoperatively; One week postoperatively or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.

  29. Left Atrial Diameter (LAD)

    The echocardiography is used to assess the LAD.

    Time frame: One day preoperatively; One week postoperatively or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.

  30. Ejection Fraction (EF)

    The echocardiography is used to assess the EF.

    Time frame: One day preoperatively; One week postoperatively or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.

  31. Fractional Shortening (FS)

    The echocardiography is used to assess the FS.

    Time frame: One day preoperatively; One week postoperatively or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.

  32. Early Diastolic Velocity/Atrial Diastolic Velocity (E/A)

    The echocardiography is used to assess the E/A.

    Time frame: One day preoperatively; One week postoperatively or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.

  33. Interventricular Septum Thickness in Diastolic (IVSTd)

    The echocardiography is used to assess the IVSTd.

    Time frame: One day preoperatively; One week postoperatively or at the date of discharge; and at 3 months, 6 months, and 1 year postoperatively.

07

Study locations

1 of 1 sites recruiting
  • Wenxue liu
    Nanjing, Jiangsu 210000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Mar 2027, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2024
First posted
Apr 11, 2024
StartActual
Nov 19, 2024
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2028
Last update
Dec 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06361238
Responsible party
Sponsor
First posted
Apr 11, 2024
Start date
Nov 19, 2024
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Dec 20, 2024

Study contacts

Wenxue Liu, PhD,MD
Contact
diligent_hi@163.com
15751866806
Dongjin Wang, PhD,MD
principal investigator · Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion